1型糖尿病患者慢性并发症与目标范围内时间及严格目标范围内时间的关联:一项回顾性横断面真实世界研究
该回顾性横断面研究纳入808例1型糖尿病成人,分析传感器测得的严格目标范围内时间(TITR:3.9-7.8 mmol/l)和目标范围内时间(TIR:3.9-10.0 mmol/l)与慢性并发症的关联;TITR和TIR与微血管并发症及脑血管意外呈负相关,校正HbA1c后TITR与任何微血管并发症、糖尿病视网膜病变、背景型糖尿病视网膜病变及脑血管意外的独立关联仍存在。
要点
- 平均TITR为33.9±12.8%,平均TIR为52.5±15.0%。
- 任何微血管并发症、糖尿病视网膜病变、糖尿病肾病及脑血管意外的患病率随TITR/TIR四分位数增加而下降(所有趋势p<0.05)。
- 校正HbA1c后,TITR每增加10%与任何微血管并发症、糖尿病视网膜病变、背景型糖尿病视网膜病变及脑血管意外的独立关联仍存在。
核心结论
- 在1型糖尿病患者中,TITR和TIR与微血管并发症及脑血管意外的存在呈负相关。
- 虽然本研究并非为确立因果关系而设计,但该分析为将TITR和TIR用作血糖管理的关键指标增加了有效性依据。
研究设计与样本
- 回顾性横断面真实世界研究,纳入808例1型糖尿病成人,根据传感器测得的TITR/TIR分析微血管并发症(糖尿病视网膜病变、糖尿病肾病和糖尿病周围神经病变[DPN])及大血管并发症的患病率。
- 采用二元逻辑回归评估TITR/TIR与并发症存在的关联,分别进行未校正、校正HbA1c、以及校正HbA1c和其他混杂因素(性别、年龄、糖尿病病程、BMI、血压、血脂谱、吸烟、他汀类和肾素-血管紧张素-醛固酮系统抑制剂使用)的分析。
- 试验注册:ClinicalTrials.gov NCT02601729 和 NCT02898714。
主要发现
- 平均TITR为33.9±12.8%,平均TIR为52.5±15.0%。
- 总体中,46.0%存在任何微血管并发症(34.5%糖尿病视网膜病变、23.8%糖尿病肾病、16.0%DPN),16.3%患有任何大血管并发症。
- 任何微血管并发症、糖尿病视网膜病变、糖尿病肾病及脑血管意外(CVA)的患病率随TITR/TIR四分位数增加而下降(所有趋势p<0.05)。
- TITR每增加10%与任何微血管并发症(OR 0.762;95% CI 0.679, 0.855;p<0.001)、糖尿病视网膜病变(OR 0.757;95% CI 0.670, 0.856;p<0.001)、背景型糖尿病视网膜病变(OR 0.760;95% CI 0.655, 0.882;p<0.001)、严重糖尿病视网膜病变(OR 0.854;95% CI 0.731, 0.998;p=0.048)、糖尿病肾病(OR 0.799;95% CI 0.699, 0.915;p<0.001)、DPN(OR 0.837;95% CI 0.717, 0.977;p=0.026)及CVA(OR 0.651;95% CI 0.470, 0.902;p=0.010)的较低发生率相关。
- 校正HbA1c后,TITR与任何微血管并发症(OR 0.867;95% CI 0.762, 0.988;p=0.032)、糖尿病视网膜病变(OR 0.837;95% CI 0.731, 0.959;p=0.010)、背景型糖尿病视网膜病变(OR 0.831;95% CI 0.705, 0.979;p=0.027)及CVA(OR 0.619;95% CI 0.426, 0.899;p=0.012)的独立关联仍存在;校正HbA1c和其他混杂因素后获得相似结果。
临床怎么用
- 作者认为,该分析为将TITR和TIR用作血糖管理的关键指标增加了有效性依据。
局限性
- 本研究并非为确立因果关系而设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to evaluate the association of chronic complications with time in tight range (TITR: 3.9-7.8 mmol/l) and time in range (TIR: 3.9-10.0 mmol/l) in people with type 1 diabetes. METHODS: The prevalence of microvascular complications (diabetic retinopathy, diabetic nephropathy and diabetic peripheral neuropathy [DPN]) and macrovascular complications according to sensor-measured TITR/TIR was analysed cross-sectionally in 808 adults with type 1 diabetes. Binary logistic regression was used to evaluate the association between TITR/TIR and the presence of complications without adjustment, with adjustment for HbA1c, and with adjustment for HbA1c and other confounding factors (sex, age, diabetes duration, BMI, BP, lipid profile, smoking, and use of statins and renin-angiotensin-aldosterone system inhibitors). RESULTS: The mean TITR and TIR were 33.9 ± 12.8% and 52.5 ± 15.0%, respectively. Overall, 46.0% had any microvascular complication (34.5% diabetic retinopathy, 23.8% diabetic nephropathy, 16.0% DPN) and 16.3% suffered from any macrovascular complication. The prevalence of any microvascular complication, diabetic retinopathy, diabetic nephropathy and a cerebrovascular accident (CVA) decreased with increasing TITR/TIR quartiles (all ptrend<0.05). Each 10% increase in TITR was associated with a lower incidence of any microvascular complication (OR 0.762; 95% CI 0.679, 0.855; p<0.001), diabetic retinopathy (OR 0.757; 95% CI 0.670, 0.856; p<0.001), background diabetic retinopathy (OR 0.760; 95% CI 0.655, 0.882; p<0.001), severe diabetic retinopathy (OR 0.854; 95% CI 0.731, 0.998; p=0.048), diabetic nephropathy (OR 0.799; 95% CI 0.699, 0.915; p<0.001), DPN (OR 0.837; 95% CI 0.717, 0.977; p=0.026) and CVA (OR 0.651; 95% CI 0.470, 0.902; p=0.010). The independent association of TITR with any microvascular complication (OR 0.867; 95% CI 0.762, 0.988; p=0.032), diabetic retinopathy (OR 0.837; 95% CI 0.731, 0.959; p=0.010), background diabetic retinopathy (OR 0.831; 95% CI 0.705, 0.979; p=0.027) and CVA (OR 0.619; 95% CI 0.426, 0.899; p=0.012) persisted after adjustment for HbA1c. Similar results were obtained when controlling for HbA1c and other confounding factors. CONCLUSIONS/INTERPRETATION: TITR and TIR are inversely associated with the presence of microvascular complications and CVA in people with type 1 diabetes. Although this study was not designed to establish a causal relationship, this analysis adds validity to the use of TITR and TIR as key measures in glycaemic management. TRIAL REGISTRATION: ClinicalTrials.gov NCT02601729 and NCT02898714.
引用
- De Meulemeester J, Charleer S, Visser MM, et al. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024. PMID: 38787436. doi:10.1007/s00125-024-06171-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。